Chemical formula: C₃₂H₃₁BrN₂O₂ Molecular mass: 555.505 g/mol PubChem compound: 5388906
Bedaquiline is a diarylquinoline. Bedaquiline specifically inhibits mycobacterial ATP (adenosine 5'-triphosphate) synthase, an essential enzyme for the generation of energy in Mycobacterium tuberculosis. The inhibition of ATP synthase leads to bactericidal effects for both replicating and non-replicating tubercle bacilli.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J04AK05 | J Antiinfectives for systemic use → J04 Antimycobacterials → J04A Drugs for treatment of tuberculosis → J04AK Other drugs for treatment of tuberculosis | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| SIRTURO Tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Bedaquiline is an active ingredient of these brands:
United States (US)
Austria (AT)
Croatia (HR)
Cyprus (CY)
Estonia (EE)
Finland (FI)
France (FR)
Hong Kong (HK)
Ireland (IE)
Israel (IL)
Italy (IT)
Japan (JP)
Lithuania (LT)
Netherlands (NL)
New Zealand (NZ)
Poland (PL)
Romania (RO)
South Africa (ZA)
Spain (ES)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
